Lipoprotein(a) and atherogenesis

Trends in Cardiovascular Medicine

Volumn 4, Issue 1, 1994, Pages 40-44

  Liu, Alexander C ^a   Lawn, Richard M ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LIPOPROTEIN A;

ANIMAL EXPERIMENT; ANIMAL MODEL; ATHEROGENESIS; ATHEROSCLEROSIS; BINDING SITE; CELL PROLIFERATION; CONTROLLED STUDY; LIPID METABOLISM; LIPID STORAGE; LIPID TRANSPORT; NONHUMAN; PLASMINOGEN ACTIVATION; PRIORITY JOURNAL; RISK ASSESSMENT; SHORT SURVEY; SMOOTH MUSCLE FIBER;

EID: 0028347665     PISSN: 10501738     EISSN: None     Source Type: Journal    
DOI: 10.1016/1050-1738(94)90024-8     Document Type: Short Survey

References (53)

1. The increased plasma Lp(a): B lipoprotein particle concentration in angina pectoris is not associated with hypofibrinolysis
2. Isolation characterisation and uptake into human fibroblasts of an apo(a)-free lipoprotein obtained on reduction of lipoprotein(a)
3. Lysine-binding heterogeneity of Lp(a): consequences for fibrin binding and inhibition of plasminogen activation.
4. Cholesterol loading of macrophages leads to marked enhancement of native lipoprotein(a) and apoprotein(a) internalization and degradation
5. Effectiveness of diet and drugs in the treatment of patients with elevated Lp(a) levels
6. Plasma lipoproteins: teaching old dogmas new tricks
7. Reconstitution of lipoprotein(a) by infusion of human LDL into transgenic mice expressing human apolipoprotein(a)
8. Quantitation and localization of apolipoproteins(a) and B in coronary artery bypass vein grafts resected at re-operation
9. In vitro studies of the interaction of isolated Lp(a) lipoprotein and other serum lipoproteins with glycosaminoglycans
10. Fibrinolytic parameters and lipoprotein (a) levels in plasma of patients with coronary artery disease
11. Relationships between lipoprotein(a), lipids, apolipoproteins, basal and stimulated fibrinolytic regulators, and D-dimer
12. The proliferation of human smooth muscle cells is promoted by lipoprotein(a)
13. Malondialdehyde modification of lipoprotein(a) produces avid uptake by human monocyte-macrophages
14. Plasmin catalyzes binding of lipoprotein(a) to immobilized fibrinogen and fibrin
15. Usefulness of serum lipoprotein(a) as a predictor of restenosis after percutaneous transluminal coronary angioplasty
16. Relationship of lipoprotein(a) to variables of coagulation and fibrinolysis in a healthy population
17. Serum Lp(a) level as a predictor of vein graft stenosis after coronary artery bypass surgery in patients
18. Overexpression of human low density lipoprotein receptors leads to accelerated catabolism of Lp(a) lipoprotein in transgenic mice
19. Familial defective apolipoprotein B-100: low density lipoproteins with abnormal receptor binding
20. Catabolism of lipoprotein (a) in familial hypercholesterolaemic subjects
21. Lipoprotein(a) inhibits the generation of transforming growth factor beta: an endogenous inhibitor of smooth muscle cell migration
22. Lipoprotein(a) mediates high affinity low density lipoprotein association to receptor negative fibroblasts
23. Studies on the role of specific cell surface receptors in the removal of lipoprotein(a) in man
24. Lipoprotein(a) is the major apoB-containing lipoprotein in the plasma of a hibernator, the hedgehog
25. Lipoprotein(a) in heart disease
26. Atherogenesis in transgenic mice expressing human apoliprotein(a)
27. Lp(a) lipoprotein enters cultured fibroblasts independently of the plasma membrane low density lipoprotein receptor
28. cDNA sequence of human apolipoprotein (a) is homologous to plasminogen
29. Thrombosis and atherogenesis: molecular connections
30. Lipoprotein(a) in dietinduced atherosclerosis in nonhuman primates
31. Oxidative modification of lipoprotein(a) and the effect of β-carotene
32. Probucol protects lipoprotein(a) against oxidative modification
33. Transient increase of plasma lipoprotein(a) in patients with unstable angina pectoris: does lipoprotein(a) alter fibrinolysis?
34. Quantification of apo(a) and apoB in human atherosclerotic lesions
35. Detection and quantification of lipoprotein(a) in the arterial wall of 107 coronary bypass patients
36. Lp(a) lipoprotein as a risk factor for myocardial infarction
37. Lipoprotein(a) and coronary heart disease: a prospective case-control study in a population sample of middle aged men
38. The pathogenesis of atherosclerosis: a perspective for the 1990s
39. Apolipoprotein(a) and plasminogen interactions with fibrin: a study with recombinant apolipoprotein(a) and isolated plasminogen fragments
40. Lipoprotein(a) binds to fibronectin
41. Lipoprotein (a): heterogeneity and biological significance
42. Lipoprotein(a) and atherosclerosis
43. Rhesus monkey lipoprotein(a) binds to lysine sepharose and U937 monocytoid cells less efficiently than human lipoprotein(a)
44. Does lipoprotein(a) (Lp(a)) compete with plasminogen in human atherosclerotic lesions and thrombi?
45. Comparative binding and degradation of lipoprotein(a) and low density lipoprotein by human monocyte-derived macrophages
46. Interaction of lipoprotein Lp(a) with the B/E receptor: a study using isolated bovine adrenal cortex and human fibroblast receptors
47. Interrelationships between plasma levels of plasminogen activator inhibitor, tissue plasminogen activator, lipoprotein(a), and established cardiovascular risk factors in a North Swedish population
48. Glutamine/histidine polymorphism in apo A-IV affects plasma concentrations of lipoprotein(a) and fibrin split products in coronary heart disease patients
49. Mechanisms by which lipoprotein lipase alters cellular metabolism of lipoprotein(a), low density lipoprotein, and nascent lipoproteins
50. Occlusive arterial thrombosis in cynomolgus monkeys with varying plasma concentrations of lipoprotein(a)
51. Role of oxidized low density lipoprotein in atherogenesis
52. Interaction of recombinant apolipoprotein(a) and Lp(a) with macrophages
53. The relationship of lipoprotein(a) with atherosclerosis